Modality
small molecule (oral)
Mechanism
JAK1-selective inhibitor
Targets
JAK1
Storage
room temperature
Approved
atopic dermatitis — FDA 2022
In trial
alopecia areata, hidradenitis suppurativa, vitiligo
Black-box warnings
serious infections; mortality; malignancy; MACE; thrombosis
Pregnancy
avoid
Monitoring
TB, HBV/HCV/HIV, CBC, lipids, LFTs, lymphocytes
Source
Last verified
2026-04-14
Mechanism of action
Rinvoq label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug